Department of Clinical Research, Jamia Hamdard School of Chemical and Life Sciences, Delhi, New Delhi, India.
Department of Medicine, Hindu Rao Hospital, Delhi, New Delhi, India.
Expert Opin Biol Ther. 2024 Nov;24(11):1261-1269. doi: 10.1080/14712598.2024.2416947. Epub 2024 Nov 12.
Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern the monoclonal antibody that offers the optimal balance of efficacy and safety for individuals with AD.
A systematic search was conducted across databases such as PubMed, Cochrane Library, and clinical trial registries for randomized controlled trials. The quality of studies was assessed using the Cochrane risk of bias 2 tool. Cognitive function and daily activities were evaluated using MMSE, ADAS-Cog, and CDR-SB test data.
According to CDR-SB measurements, lecanemab showed effectiveness in reducing brain amyloid and cognitive decline, with a change from baseline of 1.21. Aducanumab resulted in a decrease of -0.39 (-22%). Bapineuzumab showed no significant benefit, with scores of 2.4 (2.8). Gantenerumab, scoring 1.69 (1.37, 2.01), reduces amyloid, particularly in early Alzheimer's stages. Crenezumab was ineffective, with a score of 3.61.
The findings provide various perspectives. Lecanemab showed the most promise in brain amyloid reduction and decelerating cognitive decline compared to the other therapies. Further research is needed, highlighting the necessity of AD therapeutic research to alter AD's trajectory and provide reliable treatment.
www.crd.york.ac.uk/prospero identifier is CRD42024504358.
阿尔茨海默病可通过脑实质降解导致痴呆。本研究按照 PRISMA 2020 指南，调查了用于 AD 治疗的单克隆抗体，旨在确定对 AD 患者具有最佳疗效和安全性平衡的单克隆抗体。
通过对 PubMed、Cochrane 图书馆和临床试验注册中心等数据库进行系统检索，纳入了随机对照试验。使用 Cochrane 偏倚风险 2 工具评估研究质量。使用 MMSE、ADAS-Cog 和 CDR-SB 测试数据评估认知功能和日常活动。
根据 CDR-SB 测量，仑卡奈单抗在减少脑淀粉样蛋白和认知下降方面显示出有效性，从基线变化 1.21。阿杜卡奴单抗导致下降-0.39（-22%）。巴尼单抗显示无显著获益，评分 2.4（2.8）。甘特尼单抗评分 1.69（1.37，2.01）可减少淀粉样蛋白，特别是在早期阿尔茨海默病阶段。克伦单抗无效，评分为 3.61。
这些发现提供了不同的视角。与其他疗法相比，仑卡奈单抗在减少脑淀粉样蛋白和减缓认知下降方面显示出最大的潜力。需要进一步研究，强调需要进行 AD 治疗研究，以改变 AD 的轨迹并提供可靠的治疗方法。
www.crd.york.ac.uk/prospero 标识符为 CRD42024504358。
